Comparing Full-Dose Anticoagulant Therapy Alone Versus Combined Anticoagulant and Antiplatelet Therapy in Adults with Acute Venous Thromboembolism and Stable Atherosclerotic Cardiovascular Disease

What this Trial Is About

This trial investigates the best antithrombotic treatment for patients with acute venous thromboembolism VTE who are also taking antiplatelet therapy due to a history of stable atherosclerotic cardiovascular disease. VTE and atherosclerotic cardiovascular disease share common risk factors and often occur together, requiring the use of anticoagulant and antiplatelet drugs. The study aims to compare the benefits and risks of two treatment strategies to address concerns about bleeding and cardiovascular events in these patients. Participants will be randomly assigned to one of two groups. The experimental group will receive full-dose anticoagulant therapy alone, stopping antiplatelet therapy. The control group will continue combined full-dose anticoagulant and antiplatelet therapies, including aspirin or clopidogrel. Anticoagulant treatment will be given according to international guidelines for deep vein thrombosis DVT or pulmonary embolism PE, and treatment duration will be up to 12 months. During the study, participants will be monitored for clinically relevant bleeding, recurrent VTE, and major adverse ischemic cardiovascular and cerebrovascular events MACCE. Researchers will evaluate safety and effectiveness across these outcomes at the end of the treatment period. Secondary measures include non-major bleeding, arterial events, and VTE complications. The study involves regular assessments over up to one year to determine which treatment strategy offers the best overall clinical benefit.

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets